24 Sep 2020 07:00
Yourgene Health plc
("Yourgene" or the "Company")
Director/PDMR Shareholding
Manchester, UK - 24 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it was notified today of the following directors' share purchases.
The following directors have made the following share purchases on 23 September 2020:
Director | Purchase price | Number of shares purchased | Total number of shares owned following purchase | Percentage of issued share capital held following purchase |
Adam Reynolds | 17 pence | 294,117 | 6,743,773 | 0.92% |
Lyn Rees | 17 pence | 294,000 | 1,037,902 | 0.14% |
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 investors@yourgene-health.com | ||
Barry Hextall, Chief Financial Officer |
| ||
Joanne Cross, Director of Marketing |
| ||
|
| ||
Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 | ||
Liam Murray / James Caithie / Ludovico Lazzaretti | |||
N+1 Singer (Joint Corporate Broker) | Tel: +44 (0)20 7496 3000 | ||
Aubrey Powell / Tom Salvesen / George Tzimas |
| ||
|
| ||
Stifel Nicolaus Europe Limited (Joint Corporate Broker) | Tel: +44 (0)20 7710 7600 | ||
Nicholas Moore / Matthew Blawat / Ben Maddison |
| ||
|
| ||
|
| ||
Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com | ||
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / Mob: 07584 391 303 | ||
|
|
| |
About Yourgene Health plc
Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and molecular genetics. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.
Yourgene is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | a) Adam Reynolds b) Lyn Rees
| |||||
2 | Reason for notification |
| |||||
a. | Position/Status | a) Non-executive Chairman b) Chief Executive Officer | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Yourgene Health plc | |||||
b. | LEI | 213800UUIT8BZE7QEH33 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of 0.1p each
ISIN: GB00BN31ZD89 | |||||
b. | Nature of the transaction | Purchase | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) | Volume(s) | ||||||
a) 17p b) 17p | a) 294,117 b) 294,000 | ||||||
| |||||||
e. | Date of the transaction | 23 September 2020 | |||||
f. | Place of the transaction | London Stock Exchange | |||||